For instance, Allard and colleagues [19] recently showed that ADORA2A is a suppressor of NASH-associated hepatocellular cancer and that low ADORA2A correlates with poorer survival, consistent with our results in our pan-cancer cohort; they suggest that ADORA2A may have a previously unrecognized tumor suppressor function in the liver. Here, ADORA2A is linked to hepatocellular carcinoma.